Definium Therapeutics, Inc.
DFTX
Rangering i aksjer
#3484
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aksjekurs
$35.98
Markedsverdi
$4.83B
Endring (1 dag)
1.39%
Endring (1 år)
239.49%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Aksjeprishistorikk for Definium Therapeutics, Inc. (DFTX)
Høyeste sluttskurs: $10.57 den 2024-04-01
Laveste sluttskurs: $4.87 den 2020-03-01
Laveste sluttskurs: $4.87 den 2020-03-01
Aksjeprishistorikk for Definium Therapeutics, Inc. fra 2020 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $534.84 | 25.42% |
US
|
|
| $189.00 | 603.91% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $888.12 | 9.08% |
NL
|
